We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Proteomics-based Blood Test May Replace Biopsy for Diagnosis of Liver Disease

By LabMedica International staff writers
Posted on 06 Jun 2022

A mass spectroscopy-based proteomics assay was able to predict whether an individual subject was afflicted by alcohol-related liver disease and whether the individual was at risk of disease progression. More...

Alcohol-related liver disease (ALD) is a common chronic liver disorder, which affects nearly 25% of the world's population and frequently progresses to cirrhosis. With rising incidence rates, ALD has become the leading cause for liver transplantation and is responsible for more than half of all liver-related deaths. ALD progresses through a range of histological lesions, starting with alcohol-related fatty liver, to subclinical steatohepatitis featuring hepatic inflammation, which drives progressive fibrosis ultimately leading to cirrhosis.

Currently an invasive liver biopsy is the preferred method for detecting ALD despite the risk of complications such as bleeding and infection. Since approximately 75% of patients with ALD are diagnosed only after cirrhosis has occurred, making them ineligible for optimal drug treatment, detection of ALD at an early, asymptomatic stage could provide opportunities for slowing or preventing disease progression.

Searching for a non-invasive approach for diagnosis of ALD, investigators at the Max Planck Institute of Biochemistry (Munich, Germany) and the Novo Nordisk Foundation Center for Protein Research (Hellerup, Denmark) explored the diagnostic and prognostic capability of plasma proteomics in 596 individuals (137 controls and 459 individuals with ALD), 360 of whom had biopsy-based histological assessment.

The investigators analyzed all plasma samples and 79 liver biopsies using a mass spectrometry (MS)-based proteomics workflow with short gradient times and an enhanced, data-independent acquisition scheme in only three weeks of measurement time.

Results of the analyses revealed that in plasma and liver biopsy tissues, metabolic functions were downregulated whereas fibrosis-associated signaling and immune responses were upregulated. Machine learning models identified proteomics biomarker panels that detected significant fibrosis and mild inflammation more accurately than existing clinical assays. These biomarker panels were found to be accurate in prediction of future liver-related events and all-cause mortality.

Senior author Dr. Matthias Mann, director of the proteomics and signal transduction group at the Max Planck Institute of Biochemistry, said, "We are interested in rolling this out as a screening tool for the general population or at-risk populations, such as alcohol over-users, for early detection of liver diseases. We will continue biomarker development with mass spectrometry-based analysis for its specificity and systematic aspects, among other advantages. Further, we want to develop other assays for other diseases as well."

The ALD study was published in the June 2, 2022, online edition of the journal Nature Medicine.

Related Links:
Max Planck Institute of Biochemistry 
Novo Nordisk Foundation Center for Protein Research 


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The Volition Nu.Q nucleosome assay runs on the IDS i10 automated analyzer platform (Photo courtesy of VolitionRx)

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.